MedWatch

Analyst identifies difficult growth conditions for Demant ahead of Q2 report

Several factors will have hampered growth conditions for the Danish hearing aid manufacturer in recent months, a Jyske Bank analyst points out.

Photo: Demant / PR

A more difficult basis for comparisons alongside Covid-19 lockdowns, primarily in China, have made conditions more difficult for Demant, according to Jyske Bank analyst Janne Vincent Kjær prior to the release of the company’s second quarterly report.

These factors has made for a tougher second quarter than the year’s first three months, which is reflected in the analyst consensus estimate for the Danish hearing aid manufacturer that has dropped several times over the summer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs